Tesamorelin

Tesamorelin is a synthetic version of the complete forty-four-residue growth hormone–releasing hormone with a fatty acid group attached to one end. Where other analogues in this family shorten the hormone or edit the residues an enzyme recognises, this one keeps the full sequence and adds a chemical cap that hinders the enzyme physically.

It is the only GHRH analogue currently holding marketing authorisation. It is approved for one specific condition — the accumulation of deep abdominal fat seen in some people with HIV on long-term antiretroviral medication — it went through the full sequence of controlled trials, which makes its human pharmacology unusually well documented.

What draws research interest is where the effect was measured. The trials found reductions specifically in visceral adipose tissue, the fat surrounding the internal organs, rather than in fat overall. Visceral and subcutaneous fat behave as distinct tissues with distinct metabolic consequences, and a compound that appears to distinguish between them is a useful instrument for studying why.

• Visceral fat as a distinct tissue: Fat around the organs is metabolically active in ways the fat under the skin is not, and is more strongly associated with metabolic disease. A compound whose measured effect concentrates there is a tool for investigating that difference.

• Full-length stabilisation: It protects the hormone by adding a group rather than by truncating or substituting. Comparing it with the shortened analogues shows two different chemical answers to the same enzymatic problem.

• Documented human pharmacology: Completed trials mean its effects on growth hormone and IGF-1 in people are recorded in the peer-reviewed literature, giving other work in this family a measured benchmark rather than an inferred one.

• Liver fat research: Later studies extended to fat accumulation in the liver, a related but separate question, and represent one of the few areas where this class has been examined in a defined patient population.

The signal that reaches the pituitary is unchanged: this is GHRH, and the receptor reads it as GHRH. The modification is at the level of survival rather than message. A hexenoyl group attached to the first residue sits over the region DPP-4 would otherwise cut, obstructing the enzyme by occupying the space rather than by altering the sequence the receptor recognises.

Growth hormone reaching the liver prompts production of IGF-1, which carries out much of what growth hormone is credited with. Growth hormone also acts directly on fat tissue, promoting the breakdown of stored triglyceride. Both arms are in play, and separating them is one of the persistent difficulties in interpreting results from this class of compound.

Why the measured effect concentrated in visceral fat is not fully settled. Visceral adipose tissue differs from subcutaneous in its blood supply, its receptor density and the signalling molecules it releases, and any of these could account for a differential response. The observation is solid; the explanation for it remains an active research question rather than a closed one.

Tesamorelin has an unusually complete evidence base. Randomised placebo-controlled trials with imaging endpoints support its approved indication, and the effect on visceral adipose tissue was measured directly by CT rather than inferred from body weight. Its pharmacokinetics and monitoring requirements are documented in the peer-reviewed literature.

The evidence concerns one patient population under medical supervision, and material supplied for research is not the licensed pharmaceutical product; it is supplied for laboratory research only. It is the only GHRH analogue holding a current marketing authorisation, and the trial data behind it — imaging endpoints, measured directly — gives the rest of this family a documented benchmark rather than an inferred one.

Sermorelin and CJC-1295 occupy the same receptor and illustrate the alternative strategies: shortening the hormone to its active core, editing the residues an enzyme reads, or — here — capping the full sequence. All three arrive at the same pituitary receptor by different chemical routes.

Ipamorelin approaches the same cell through the ghrelin receptor instead, which is a separate door into the same room. Comparisons across the two families are common in research discussion because the endpoint measured is often the same even when the mechanism is not.